Abstract:Constructing an effective therapeutic cancer vaccine is very attractive and promising for cancer immunotherapy. However, the poor immunogenicity of tumor antigens and suppression of the immune system in the tumor microenvironment are two major obstacles for developing effective cancer vaccines. Invariant NKT cells (iNKT cells), which are essential bridges between the innate and adaptive immune systems, can be rapidly activated by their agonists and, consequently, evoke whole immune systems. Herein, we conjugated a potent agonist of the iNKT cell, α-galactosylceramide (α-GalCer), with the tumor-associated MUC1 glycopeptide antigens as novel self-adjuvanting cancer vaccines through click chemistry. Immunological studies revealed that the mouse immune system was potently evoked and that high levels of tumor-specific IgG antibodies were elicited by vaccine conjugates without an external adjuvant. The produced antibodies could specifically recognize and bind to antigen-expressing cancer cells and, subsequently, induce cytotoxicity through complement-dependent cytotoxicity. Thus, the insertion of α-GalCer significantly improved the immunogenicity of the MUC1 glycopeptide and induced strong antigen-specific antitumor responses, indicating that α-GalCer is an effective built-in adjuvant for constructing potent chemical synthetic antitumor vaccines.

Synthesis and Evaluation of Liposomal Anti-GM3 Cancer Vaccine Candidates Covalently and Noncovalently Adjuvanted by αGalCer

Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen

Synthesis of DNP-modified GM3-based anticancer vaccine and evaluation of its immunological activities for cancer immunotherapy

Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies

Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.

Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly As an Antitumor Vaccine.

Synthesis and Biological Activities of Amino Acids Functionalized Α-Galcer Analogues.

Synthesis and Immunological Evaluation of MUC1 Glycopeptide Conjugates Bearing N-acetyl Modified STn Derivatives As Anticancer Vaccines.

Synthesis and immunological evaluation of <i>N</i>-acyl modified Globo H derivatives as anticancer vaccine candidates

Poly(I:C)/c-GAMP/Alum ternary adjuvant system synergistically enhances the immunogenicity of glycopeptide antigen

One-Pot Enzymatic Synthesis and Biological Evaluation of Ganglioside GM3 Derivatives as Potential Cancer Immunotherapeutics

Liposome-Based Carbohydrate Vaccine for Simultaneously Eliciting Humoral and Cellular Antitumor Immunity

Synthesis and immunological evaluation of Mincle ligands-based antitumor vaccines

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

Fully Synthetic Self-Adjuvanting Thioether-Conjugated Glycopeptidelipopeptide Antitumor Vaccines For The Induction Of Complement-Dependent Cytotoxicity Against Tumor Cells

Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S‐configured Pam3CysSerLys4

Design, Synthesis, and Bioactivity Evaluation of a TF-Based Cancer Vaccine Candidate Using Lipid A Mimetics As a Built-In Adjuvant

Synthesis and Evaluation of Glycoconjugates Comprising N‐Acyl‐Modified Thomsen–Friedenreich Antigens As Anticancer Vaccines

Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.

Synthesis and Immunological Evaluation of N-acyl Modified Tn Analogues As Anticancer Vaccine Candidates.

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine